Here are the DEF 14A proxy statements from Edesa Biotech, Inc. (EDSA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow EDSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EDSA filings page.
Edesa Biotech, Inc. is asking shareholders to vote at its 2026 Annual General and Special Meeting on May 27, 2026. Owners of 8,885,719 common shares outstanding as of March 30, 2026 may vote.
Shareholders will be asked to elect seven directors, approve an advisory say-on-pay vote on executive compensation, amend the 2019 Equity Incentive Compensation Plan to add 750,000 shares and remove the annual per‑participant option grant limit, and ratify MNP LLP as auditor for the fiscal year ending September 30, 2026. The proxy also details board structure, committee independence, executive and director pay, equity award holdings, and change‑of‑control severance terms for senior executives.